Earlier today, Nautilus Biotechnology released financial results for the quarter ended March 31, 2026. If you haven't received this news release or if you'd like to be added to the company's ...
Cochlear, CSL and Pro Medicus have been hard hit by disparate concerns, many of which investors suspect are structural rather ...
Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets ...
Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...
Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...
If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares ...
We'll know more about the company's medium-term prospects by the end of the year.
Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting preclinical data from SG293, ...
Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of ...
Boehringer Ingelheim’s glucagon/GLP-1 dual agonist has driven 16.6% weight loss at Week 76 of a phase 3 study. While the ...
Crucially, Royalty Pharma’s model removes a lot of the volatility arising from development risk. By focusing on approved or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results